This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for
the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior
Disorder (RBD) in subjects with Lewy body dementia (LBD).

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Lewy Body Dementia

Dementia With Lewy Bodies

Parkinson's Disease Dementia

Visual Hallucinations

REM Sleep Behavior Disorder

This is a multi-center open-label, long-term study in LBD subjects with RBD and/or VHs.
Eligible subjects who completed a previous nelotanserin VH or RBD study and choose to
participate in this open-label study will receive 20, 40, 60, or 80 mg nelotanserin once
daily for 24 weeks.

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?

Locations

Location

Status